Advanced Biliary Tract Cancer clinical trials

Explore recruiting advanced biliary tract cancer clinical trials.

Recruiting advanced biliary tract cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Biliary Tract Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

SEVILLA_A randomised, phase II trial to evaluate the efficacy of ivonescimab, a PD 1/VEGF bispecific antibody, versus FOLFOX as second line therapy for locally advanced or metastatic biliary tract cancers

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1)

Poland, Bulgaria, Italy, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).

Germany, Poland, Italy, Belgium, France, Netherlands +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Advanced Biliary Tract Cancer trials by city

Advanced Biliary Tract Cancer clinical trials

Recruiting advanced biliary tract cancer studies right now

Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer

Study for AZD4360 in Participants With Advanced Solid Tumours

A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients

Also recruiting in Europe

SEVILLA_A randomised, phase II trial to evaluate the efficacy of ivonescimab, a PD 1/VEGF bispecific antibody, versus FOLFOX as second line therapy for locally advanced or metastatic biliary tract cancers

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1)

Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).

Advanced Biliary Tract Cancer trials by city

Other conditions